FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Real-time Bid/Ask 04:20:14 2024-06-17 EDT | ||
| 1271.19 EUR / 1272.55 EUR | -0.91% |
|
| Current month | +20.07% | ||
| 1 month | +21.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 1,284 | +1.20% |
| 24-06-13 | 1,268 | +0.65% |
| 24-06-12 | 1,260 | +0.85% |
| 24-06-11 | 1,250 | -1.29% |
| 24-06-10 | 1,266 | +3.11% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 11:34 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MF1GUE |
| ISIN | DE000MF1GUE3 |
| Date issued | 2017-02-06 |
| Strike | 661 kr |
| Maturity | Unlimited |
| Parity | 0.03 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,284 € |
|---|---|
| Lowest since issue | 9.4 € |
| Spread | 1.36 € |
| Spread % | 0.11% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Certificates
- Certificat
